Bio-Reference Labs (BRLI +6.5%) pops after BofA Merrill Lynch ups the shares to Buy, citing how the returns on the commercialization of its high-end tests in a number of high-growth specialty niches are starting to bear fruit. Additionally, reimbursement headwinds and new billing codes are more likely to disproportionately impact small players, which gives BRLI the opportunity to capture market share.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs